Solid tumor metastases cause most cancer-related deaths. The prevention of their occurrence misses suitable anti-metastases medicines newly labeled as migrastatics. The first indication of migrastatics potential is based on an inhibition of in vitro enhanced migration of tumor cell lines. Therefore, we decided to develop a rapid test for qualifying the expected migrastatic potential of some drugs for repurposing. The chosen Q-PHASE holographic microscope provides reliable multifield time-lapse recording and simultaneous analysis of the cell morphology, migration, and growth. The results of the pilot assessment of the migrastatic potential exerted by the chosen medicines on selected cell lines are presented.

CEITEC Central European Institute of Technology Brno University of Technology Brno Czech Republic

Department of Cell Biology and Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University in Vestec Laboratory of Cancer Cell Invasion Charles University Prague Czech Republic

General University Hospital Prague Department of Clinical Pharmacology and Pharmacy Prague Czech Republic

Institute of Physical Engineering Faculty of Mechanical Engineering Brno University of Technology Brno Czech Republic

Zobrazit více v PubMed

Fares J., Fares M. Y., Khachfe H. H., Salhab H. A., Fares Y., “Molecular principles of metastasis: a hallmark of cancer revisited,” Signal Transduction Targeted Ther. 5(1), 28 (2020).10.1038/s41392-020-0134-x PubMed DOI PMC

Sleeman J., Steeg P. S., “Cancer metastasis as a therapeutic target,” Eur. J. Cancer 46(7), 1177–1180 (2010).10.1016/j.ejca.2010.02.039 PubMed DOI PMC

Gandalovičová A., Rosel D., Fernandes M., Veselý P., Heneberg P., Čermák V., Petruželka L., Kumar S., Sanz-Moreno V., Brábek J., “Migrastatics-Anti-metastatic and Anti-invasion Drugs: Promises and Challenges,” Trends Cancer 3(6), 391–406 (2017).10.1016/j.trecan.2017.04.008 PubMed DOI PMC

Fares J.D., Kanojia A., Rashidi I., Ulasov M.S., Lesniak, “Landscape of combination therapy trials in breast cancer brain metastasis,” Int. J. Cancer 147, 1939–1952 (2020).10.1002/ijc.32937 PubMed DOI PMC

Solomon J., Rašková M., Rösel D., Brábek J., Gil-Henn H., “Are We Ready for Migrastatics?” Cell 10(8), 2021 (1845).10.3390/cells10081845 PubMed DOI PMC

Rosel D., Fernandes M., Sanz-Moreno V., Brábek J., “Migrastatics: Redirecting R&D in Solid Cancer Towards Metastasis?” Trends Cancer 5(12), 755–756 (2019).10.1016/j.trecan.2019.10.011 PubMed DOI

Raudenská M., Petrláková K., Juriňáková T., Leischner Fialová J., Fojtů M., Jakubek M., Rösel D., Brábek J., Masařík M., “Engine shutdown: migrastatic strategies and prevention of metastases,” Trends Cancer 9(4), 293–308 (2023).10.1016/j.trecan.2023.01.001 PubMed DOI

Eslami Z., Cortés-Hernández S. L. E., Alix-Panabières C., “The Metastatic Cascade as the Basis for Liquid Biopsy Development,” Front. Oncol. 10, 32850309 (2020).10.3389/fonc.2020.01055 PubMed DOI PMC

Zhu Y. S., Zhu J., “Molecular and cellular functions of long non-coding RNAs in prostate and breast cancer,” Advances in clinical chemistry 106, 91–179 (2022).10.1016/bs.acc.2021.09.005 PubMed DOI

Ďuriš M., Chmelík R., “Super-Resolution in coherence-controlled holographic microscope using synthetic aperture approach,” in OSA Optical Sensors and Sensing Congress (2021).

Štrbková L., Zicha D., Veselý P., Chmelík R., “Automated classification of cell morphology by coherence-controlled holographic microscopy,” J. Biomed. Opt. 22(08), 1–9 (2017).10.1117/1.JBO.22.8.086008 PubMed DOI

Chmelík R., Slabá M., Kollárová V., Slabý T., Lošťák M., Čolláková J., “The Role of Coherence in Image Formation in Holographic Microscopy,” Prog. Opt. 267 –335 Elsevier, Amsterdam. (2014).

Slabý T., Kolman P., Dostál Z., Antoš M., Lošťák M., Chmelík R, “Off-axis setup taking full advantage of incoherent illumination in coherence-controlled holographic microscope,” Opt. Express 21(12), 14747–14762 (2013).10.1364/OE.21.014747 PubMed DOI

Vicar T., Chmelík J., Navrátil J., Kolář R., Chmelíková L., Cmiel V., Jagos J., Provazník I., Masařík M., Gumulec J., “Cancer cell viscoelasticity measurement by quantitative phase and flow stress induction,” Biophys. J. 121(9), 1632–1642 (2022).10.1016/j.bpj.2022.04.002 PubMed DOI PMC

Vicar T., Chmelík J., Jakubicek R., Chmelikova L., Gumulec J., Balvan J., Provaznik I., Kolar R., “Self-supervised pretraining for transferable quantitative phase image cell segmentation,” Biomed. Opt. Express 12(10), 6514–6528 (2021).10.1364/BOE.433212 PubMed DOI PMC

Barer R., “Interference microscopy and mass determination,” Nature 169(4296), 366–367 (1952).10.1038/169366b0 PubMed DOI

Davies H. G., Wilkins M. H. F., “Interference microscopy and mass determination,” Nature 169(4300), 541 (1952).10.1038/169541a0 PubMed DOI

Janečková H., Veselý P., Chmelík R., “Proving tumour cells by acute nutritional/energy deprivation as a survival threat: a task for microscopy,” Anticancer Res. 29(6), 2339–2345 (2009). PubMed

Hecht I., Bar-El Y., Balmer F., Natan S., Tsarfaty I., Schweitzer F., Ben-Jacob E., “Tumor invasion optimization by mesenchymal-amoeboid heterogeneity,” Sci. Rep. 5(1), 10622 (2015).10.1038/srep10622 PubMed DOI PMC

Talkenberger K., Cavalcanti-Adam E. A., Voss-Böhme A., Deutsch A., “Amoeboid-mesenchymal migration plasticity promotes invasion only in complex heterogeneous microenvironments,” Sci. Rep. 7(1), 9237 (2017).10.1038/s41598-017-09300-3 PubMed DOI PMC

Friedl P., Wolf K., “Plasticity of cell migration: a multiscale tuning model,” J. Cell Biol. 188(1), 11 (2010).10.1083/jcb.200909003 PubMed DOI PMC

Paňková K., Rösel D., Novotný M., Brábek J., “The molecular mechanisms of transition between mesenchymal and amoeboid invasiveness in tumor cells,” Cell. Mol. Life Sci. 67(1), 63–71 (2010).10.1007/s00018-009-0132-1 PubMed DOI PMC

Liu J. Y., Le Berre M., Lautenschlaeger F., Maiuri P., Callan-Jones A., Heuzé M., Takaki T., Voituriez R., Piel M., “Confinement and low adhesion induce fast amoeboid migration of slow mesenchymal cells,” Cell 160(4), 659 (2015).10.1016/j.cell.2015.01.007 PubMed DOI

Koparal A. T., Zeytinoğlu M., “Effects of Carvacrol on a Human Non-Small Cell Lung Cancer (NSCLC) Cell Line, A549,” Cytotechnology 43(1-3), 159 (2003).10.1023/b:cyto.0000039917.60348.45 PubMed DOI PMC

Bahrami A., Folpe A.L., “Adult-type fibrosarcoma: A reevaluation of 163 putative cases diagnosed at a single institution over a 48-year period,” Am. J. Surg. Pathol. 34(10), 1504 (2010).10.1097/PAS.0b013e3181ef70b6 PubMed DOI

Van den Berg E., Molenaar W. M., Hoekstra H. J., Kamps W. A., de Jong B., “DNA ploidy and karyotype in recurrent and metastatic soft tissue sarcomas,” Mod Pathol. 5(5), 505 (1992). PubMed

Limon J., Szadowska A., Iliszko M., Babińska M., Mrózek K., Jaśkiewicz A., Kopacz A., Roszkiewicz M., Debiec-Rychter, “Recurrent chromosome changes in two adult fibrosarcomas,” Genes, Chromosomes Cancer 21(2), 119 (1998).10.1002/(SICI)1098-2264(199802)21:2<119::AID-GCC7>3.0.CO;2-3 PubMed DOI

Patlolla A., Knighten B., Tchounwou P., “Multi-walled carbon nanotubes induce cytotoxicity, genotoxicity and apoptosis in normal human dermal fibroblast cells,” Ethn. Dis. 20, 65–72 (2010). PubMed PMC

Mahagita C., Tanphichai K., Suksamrarn A., Ballatori N., Piyachaturawat P., “P4-Hydroxyacetophenone-induced choleresis in rats is mediated by the Mrp2-dependent biliary secretion of its glucuronide conjugate,” Pharm. Res. 23(11), 2603–2610 (2006).10.1007/s11095-006-9097-z PubMed DOI

Bryan D. S., Stack M., Krysztofiak K., Cichoń U., Thomas D. G., Surcel A., Schiffhauer E. S., Beckett M. A., Khodarev N. N., Xue L., Poli E.C., Pearson A. T., Posner M. C., Robinson D. N., Rock R. S., Weichselbaum R. R., “4-Hydroxyacetophenone modulates the actomyosin cytoskeleton to reduce metastasis,” Proc. Natl. Acad. Sci. 117(36), 22423–22429 (2020).10.1073/pnas.2014639117 PubMed DOI PMC

Blair H. A., “Belumosudil: First Approval,” Drugs 81(14), 1677–1682 (2021).10.1007/s40265-021-01593-z PubMed DOI PMC

Graziani V., Rodriguez-Hernandez I., Maiques O., Sanz-Moreno V., “The amoeboid state as part of the epithelial-to-mesenchymal transition programme,” Trends Cell Biol. 32(3), 228–242 (2022).10.1016/j.tcb.2021.10.004 PubMed DOI

Friedman J. M., Polifka J. E., “Teratogenic Effects of Drugs,” Teris (The Johns Hopkins University Press, 2000), pp. 149–195.

Kundu C. N., Das S., Nayak A., Satapathy S. R., Das D., Siddharth S., “Anti-malarials are anti-cancers and vice versa,” Acta Tropica. 149, 113–127 (2015).10.1016/j.actatropica.2015.03.028 PubMed DOI

Koch J. C., Kuttler J., Maass F., Lengenfeld T., Zielke E., Bähr M., Lingor P., “Compassionate Use of the ROCK Inhibitor Fasudil in Three Patients with Amyotrophic Lateral Sclerosis,” Acta Trop. 11, 1 (2020).10.3389/fneur.2020.00173 PubMed DOI PMC

Huang Y.Y., Wu J. M., Su T., Zhang S. Y., Lin X. J., “Fasudil, a rho-kinase inhibitor, exerts cardioprotective function in animal models of myocardial ischemia/reperfusion injury: a meta-analysis and review of preclinical evidence and possible mechanisms,” Front. Neurol. 9, 1083 (2018).10.3389/fphar.2018.01083 PubMed DOI PMC

Stone R. M., Mandrekar S. J., Sanford B. L., Laumann K., Geyer S., Bloomfield C. D., Thiede C., Prior T. W., Döhner K., Marcucci G., Lo-Coco F., Klisovic R. B., Wei A., Sierra J., Sanz M. A., Brandwein J. M., de Witte T., Niederwieser D., “Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation,” The New England Journal of Medicine 377(5), 454–464 (2017).10.1056/NEJMoa1614359 PubMed DOI PMC

Abbas H. A., Alfayez M., Kadia T., Ravandi-Kashani F., Daver N., “Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection,” Cancer Manag Res. 4, 8817–8828 (2019).10.2147/CMAR.S177894 PubMed DOI PMC

Chai W. H., Li Y. R., Lin S. H., Chao Y. H., Chen C. H., Chan P. C., Lin C. H., “Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells In Vitro and In Vivo,” Anticancer Res. 40(3), 1405–1417 (2020).10.21873/anticanres.14082 PubMed DOI

Dakir E., Pickard A., Srivastava K., McCrudden C. M., Gross S. R., Lloyd S., Zhang S S., Margariti A., Morgan R., Rudland P. S., El-Tanani M., “The anti-psychotic drug pimozide is a novel chemotherapeutic for breast cancer,” Oncotarget 9(79), 34889–34910 (2018).10.18632/Oncotarget26175 PubMed DOI PMC

Ali F., Ilyas A., “Belumosudil with ROCK-2 inhibition: chemical and therapeutic development to FDA approval for the treatment of chronic graft-versus-host disease,” Curr. Res. Transl. Med. 70(3), 103343 (2022).10.1016/j.retram.2022.103343 PubMed DOI

Qin Y., Zhang Q., Lee S., Zhong W. L., Liu Y. R., Liu H. J., Zhao D., Chen S., Xiao T., Meng J., Jing X. S., Wang J., Sun B., Dai T. T., Yang C., Sun T., Zhou H. G., “Doxycycline reverses epithelial-to-mesenchymal transition and suppresses the proliferation and metastasis of lung cancer cells,” Oncotarget 6(38), 40667 (2015).10.18632/Oncotarget5842 PubMed DOI PMC

Garitano-Trojaola A., Sancho A., Götz R., et al. , “Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia,” Commun. Biol. 4(1), 799 (2021).10.1038/s42003-021-02215-w PubMed DOI PMC

Arend R. C., Londoño-Joshi A. I., Gangrade A., Katre A. A., Kurpad C., Li Y., Samant R. S., Li P. K., Landen C. N., Yang E. S., Hidalgo B., Alvarez R. D., Straughn J. M., Forero A., Buchsbaum D. J., “Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer,” Oncotarget 7(52), 86803–86815 (2016).10.18632/Oncotarget13466 PubMed DOI PMC

Liu J., Ding H., Quan H, Han J., “Anthelminthic niclosamide inhibits tumor growth and invasion in cisplatin-resistant human epidermal growth factor receptor 2-positive breast cancer,” Oncol. Lett. 22(3), 666 (2021).10.3892/ol.2021.12927 PubMed DOI PMC

Yeh L. T., Lin C. W., Lu K. H., Hsieh Y. H., Yeh C. B., Yang S. F., Yang J. S., “Niclosamide Suppresses Migration and Invasion of Human Osteosarcoma Cells by Repressing TGFBI Expression via the ERK Signaling Pathway,” Int. J. Mol. Sci. 23(1), 484 (2022).10.3390/ijms23010484 PubMed DOI PMC

Huang S., Li D., Zhuang L., Sun L., Wu J., “Identification of Arp2/3 Complex Subunits as Prognostic Biomarkers for Hepatocellular Carcinoma,” Front. Mol. Biosci. 8, 690151 (2021).10.3389/fmolb.2021.690151 PubMed DOI PMC

Leith E. N., Upatnieks J., “Holography with Achromatic-Fringe Systems,” J. Opt. Soc. Am. 57(8), 975 (1967).10.1364/JOSA.57.000975 DOI

Sharma S., Ghufran S. M., Ghose S., Biswas S., “Cytoplasmic vacuolation with endoplasmic reticulum stress directs sorafenib induced non-apoptotic cell death in hepatic stellate cells,” Sci. Rep. 11(1), 3089 (2021).10.1038/s41598-021-82381-3 PubMed DOI PMC